Oncternal Therapeutics to Participate in September Investor Conferences

- H.C. Wainwright 22nd Annual Global Investment Conference -
September 14^th - 16^th

- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit -
September 21^st - 23^rd

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the following conferences in the month of September and invites investors to join by webcast. Please see additional details below:

H.C. Wainwright 22nd Annual Global Investment Conference (Virtual)
	Title:	Oncternal Therapeutics (ONCT) Company Presentation
	Date:	Wednesday, September 16^th, 2020
	Time:	10:30 am Eastern Time
	Presenter:	James Breitmeyer, President & CEO
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual)
	Title:	Oncternal Therapeutics (ONCT) Company Presentation
	Date:	Tuesday, September 22^nd, 2020
	Time:	4:10 pm Eastern Time
	Presenter:	James Breitmeyer, President & CEO

Webcast Links:

Live webcasts of the presentations will be available online via a link from the investor relations page of the Company’s website at https://investor.oncternal.com/news-and-events/events-presentations, and the webcasts will be archived there for at least 30 days following the events.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, and TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.